HUTCHMED, AstraZeneca, ORPATHYS, Savolitinib, TAGRISSO, Osimertinib, SANOVO Trial, Phase 3 Clinical Trial, EGFR-Mutated NSCLC, Non-Small Cell Lung Cancer, MET Overexpression,

HONG KONG, SHANGHAI AND FLORHAM PARK, N.J. — October 26, 2026 HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) announced positive results...